Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Phase 2 Study Active, not recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Active, not recruiting
    • Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG Active, not recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Biosciences Announces Positive Data From Phase 1 Therapeutic Trial of CLR 131 in Multiple Myeloma

Jan 5, 2016

Cellectar Biosciences and Pierre Fabre Laboratories Announce Oncology Research Collaboration

Dec 16, 2015

Cellectar Biosciences to Provide Update on Phase 1 Multiple Myeloma Study

Dec 9, 2015

Cellectar Biosciences Chief Scientific Officer Receives International Recognition for Pioneering Research

Nov 20, 2015

Cellectar Biosciences Announces Third Quarter Financial Results

Nov 12, 2015

Cellectar Biosciences Converts Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles

Nov 10, 2015

Cellectar Biosciences to Host Conference Call on November 12th to Discuss Third Quarter Financial Results and Provide Clinical Development Program Update

Nov 5, 2015

Cellectar Biosciences Provides Phospholipid Drug Conjugate (PDC) Platform Development Update

Nov 2, 2015

Cellectar Biosciences to Present at the 2015 BIO Investor Forum

Oct 16, 2015

Cellectar Biosciences Closes on $3.3 Million Financing

Oct 2, 2015
    • 1...
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • 33
    • 34
    • 35
    • 36
    © 2025 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A